Entering text into the input field will update the search result below

A Risk Off Day But With Nice Gains In Biotech: ALXN, AMGN, PCYC, VRML

Jul. 10, 2013 12:24 PM ETIBB
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

ETF investing, Portfolio Strategy, Long/Short Equity

Seeking Alpha Analyst Since 2007

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a Technology Transfer Officer at UCLA. He has a B.S. from Penn State University and an MBA from Rutgers University. His WEB site at www.raygent.com is currently focused in biopharmaceuticals, genomics and clinical diagnostics . Mr. Raynovich has extensive expertise in marketing and product development and provides business development consulting to early stage companies in biotechnology, diagnostics and imaging. The Rayno Life Science Portfolio was published on www.raygent.com and other trade media. Articles have been published on the following topics: Alzheimer Disease,Biomarkers, Genomics,Molecular Diagnostics, Oncology Drugs, Personalized Medicine, Targeted Therapy, Technology Trends, H1N1 and Government Policy on biotechnology. The Life Science Portfolio is up over 80% over a 24 mo. period as of 5/30/14and among the life science portfolio winners are ABAX, ALXN, AMRI, BIIB, CBST, GPRO, ILMN, QDEL,REGN, SGEN, and VPHM.

Rayno Life Science Movers 2% or more

Alexion (ALXN $97.8) up 2.14%

Amgen (AMGN $100.71) up 2.4%

Pharmacyclics (PCYC $100.55) up 12%

Vermillion (VRML $2.90) up 10.6%

After a 4 day S&P rally up 2.7% stocks are taking a rest but the IBB ($183.56) rallied another 0.58% up 33.7% YTD just shy of its all time high of $186.98. Healthcare was the strongest sector today. Most Rayno Life Science stocks were green.

No changes have been made in our portfolios. The action in the market is encouraging with several new highs lately despite many large cap biotech stocks trading well below May highs. We reiterate need for raising some cash to at least 10% of a life science portfolio. The Fidelity Select Biotechnology Fund (FBIOX) hit a new high yesterday and is likely to hit another high today.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Additional disclosure: I am long Fidelity Select Biotech (FBIOX)

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.